Edinburgh engineers E. coli to turn PET into L‑DOPA
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- University of Edinburgh engineered E. coli bacteria to transform PET waste into L‑DOPA, a frontline Parkinson’s medication.
- E. coli breaks down PET into terephthalic acid and then synthesizes L‑DOPA through a series of engineered biological reactions.
- Carbon‑Loop Sustainable Biomanufacturing Hub provided the research platform and is funded by a £14 million EPSRC grant to develop waste‑to‑value technologies.
- Nature Sustainability published the study, which reports successful production and isolation of L‑DOPA at preparative scale.
- Stephen Wallace (lead author) says the work shows how plastic waste can be reimagined as a high‑value resource for human health and envisions broader applications beyond medicines.
- EPSRC supports the project, aiming to create a bio‑upcycling industry for pharmaceuticals, flavorings, fragrances, cosmetics, and industrial chemicals.
Why it matters: The bio‑upcycling route challenges the fossil‑fuel‑based chemical sector that currently supplies raw materials for L‑DOPA, giving pharmaceutical manufacturers a greener feedstock; it also creates value from plastic waste, potentially lowering environmental cleanup costs and opening new revenue streams for waste‑management firms while reducing reliance on non‑renewable resources.
